Tirzepatide and Cardiovascular Risk: What New Evidence—and the Updated Mounjaro Label—Mean for Type 2 Diabetes Care
Tirzepatide, sold as Mounjaro for type 2 diabetes in the United States, has become a major part of the public conversation about diabetes and metabolic health. Recent reporting has focused on two related developments: a large real-world study linking tirzepatide with fewer major cardiovascular events than a cardiovascular-neutral comparison medicine, and a new Mounjaro indication […]
Type 2 Diabetes and Brain Health: What Recent Studies on Blood Sugar and Medications Can—and Cannot—Tell Us
Type 2 diabetes is often discussed through blood glucose, weight, A1c, blood pressure, or cholesterol. Those measures matter. But people living with diabetes are also asking a broader question: What does metabolic health mean for the brain over time? Brain health belongs in the type 2 diabetes conversation That question has become more urgent as […]